Form 4: Minerva Neurosciences Director Acquires Stock Options

A director of Minerva Neurosciences, Inc. was granted stock options to purchase 12,500 shares of common stock.

Summary

• Fouzia Laghrissi-Thode, a director at Minerva Neurosciences, Inc., was granted stock options to purchase 12,500 shares of the company's common stock.
• The options were granted on December 5, 2024, at an exercise price of $2.12 per share.
• These options vest in four equal quarterly installments, starting three months after the grant date, contingent on the director's continued service.
• The options expire on December 4, 2034.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, which is generally viewed neutrally to slightly positive as it aligns interests. There is no indication of any negative or unexpected events.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule encourages the director's continued service with the company.

Industry Context

Stock option grants to directors are a common practice in publicly traded companies as part of their compensation packages.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for non-employee directors in publicly traded companies.
• The vesting schedule of quarterly installments over one year is typical for such grants.
• The exercise price of $2.12 is specific to Minerva Neurosciences and its current stock valuation.

Stakeholder Impact

• The stock option grant may have a minor positive impact on shareholder sentiment as it aligns director interests with company performance.

Key Dates

Keywords

stock options, director compensation, insider trading, Minerva Neurosciences, NERV, equity